Daan Gene Co (002030) Fair Value & Analysis
Healthcare · CN · Market cap 7.5B CNY
Fair value as of: Jul 21, 2026
From 10 valuation models · updated 20 days ago
Fair value updated Jul 21, 2026, revised from ¥1.26 to ¥0.5300 (−57.9%) since Jun 25, 2026. Share price +12.4% over the past month.
A solid business, but screening 91% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥0.5400). The favourable scenario is already priced in.
- Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.
- The models converge in a tight band (¥0.5300 to ¥0.5400), unusually little disagreement for a valuation.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range ¥4.77 – ¥19.52 · fair‑value band ¥0.5300 – ¥0.5400 · the ¥5.61 price screens above the ¥0.5300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 21, 2026.
Analysis
Daan Gene Co (002030) currently trades at ¥5.61, while our model-based Fair Value estimate is ¥0.5300, implying the stock looks roughly 90.6% overvalued today. The Quality Score stands at 50/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Trailing-twelve-month revenue stands at 738M CNY. Revenue declined 11.6% year over year. It earns a return on equity of -12.0%. The balance sheet holds a net cash position of 715M CNY. Fundamentals as of Jul 21, 2026
Our scenario range runs from ¥0.5300 (bear case) to ¥0.5400 (bull case); at ¥5.61, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 32% below its 52-week high and 7% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -91%, 002030 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 10 models by family
Widest divergence: Asset-Based (¥3.41) versus Multiples (¥0.3900). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 51 · Market factors (momentum, volatility) 38
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Daan Gene Co., Ltd., together with its subsidiaries, researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables in China. It operates through two segments, Biological Products and Related Business and Financial Business.
Full company description
Daan Gene Co., Ltd., together with its subsidiaries, researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables in China. It operates through two segments, Biological Products and Related Business and Financial Business. The company offers reagents for hepatitis virus, sexually transmitted infections, blood screening, digestive pathogens, coronavirus disease (COVID-19), pharmacogenomics, viral transport medium, human papillomavirus, human immunodeficiency virus, respiratory infections, public health, tumor maker, and nucleic acid extraction, as well as polymerase chain reaction, sample preparation, and nucleic extraction systems for molecular diagnosis; COVID-19 rapid test kit and chemiluminescence immunoassay analyzers for immunoassay; liquid based cytology production and automatic sample transfer machines for pathology tests; and auto biochemistry analyzers and chemistry reagents for clinical chemistry. It also provides medical laboratory and health consultation services, such as genetic susceptibility gene testing, tumor marker testing, cervical cancer screening, routine physical examination, and other health services. The company sells its products under the Daan Gene, Darui Biology, LBP, and Zhongshan Bio-Tech brands. In addition, it is involved in biological technology, biomedicine and biopharmaceutical, clinical test, business, software development, trading, hospital investment management, capital market, insurance agent, management, finance lease, microfinance, commercial factoring, loan, consulting, and technology promotion and application service industry services. The company was formerly known as Da An Gene Co., Ltd. of Sun Yat-Sen University. Daan Gene Co., Ltd. was founded in 1988 and is headquartered in Guangzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Daan Gene Co reported revenue of ¥758M in FY2025 versus ¥7.7B in FY2021, a compound −43.9%/yr. Reported net income was −¥744M in FY2025.
002030 screens 91% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 603 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Daan Gene Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Daan Gene Co (002030) overvalued or undervalued?
What is the fair value of 002030?
What is the quality score of 002030?
What is the revenue of Daan Gene Co (002030)?
What is the net profit margin of 002030?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Daan Gene Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.